clonidine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensives, clonidine derivatives 704 4205-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clonidine
  • clonidine hydrochloride
  • clonidine HCl
An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
  • Molecular weight: 230.09
  • Formula: C9H9Cl2N3
  • CLOGP: 1.73
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 36.42
  • ALOGS: -2.68
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.45 mg O
0.45 mg P
0.10 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.17 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine) 62 % Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.56 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 3, 1974 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Temperature regulation disorder 343.65 10.65 141 58979 4327 56228620
Completed suicide 306.01 10.65 523 58597 133310 56099637
Hypertension 271.04 10.65 710 58410 243568 55989379
Food allergy 254.98 10.65 142 58978 8682 56224265
Coeliac disease 234.07 10.65 142 58978 10197 56222750
Immunodeficiency 176.77 10.65 142 58978 16015 56216932
Bursitis 174.33 10.65 178 58942 27404 56205543
Cardiac failure congestive 166.05 10.65 316 58804 87404 56145543
Drug withdrawal syndrome 154.64 10.65 162 58958 25695 56207252
Bradycardia 150.37 10.65 261 58859 67243 56165704
Hyperhidrosis 144.77 10.65 311 58809 93777 56139170
Mental status changes 137.67 10.65 183 58937 37318 56195629
Hypertensive crisis 136.07 10.65 115 59005 13921 56219026
Synovitis 134.21 10.65 9 59111 161296 56071651
Glossodynia 122.58 10.65 10 59110 152448 56080499
Blood pressure increased 114.47 10.65 374 58746 144802 56088145
Overdose 112.33 10.65 303 58817 105527 56127420
Rash erythematous 111.83 10.65 165 58955 37056 56195891
Systemic lupus erythematosus 111.76 10.65 26 59094 180052 56052895
Blood pressure inadequately controlled 109.82 10.65 65 59055 4459 56228488
Drug intolerance 106.50 10.65 74 59046 264744 55968203
Arthropathy 104.19 10.65 40 59080 200235 56032712
Joint swelling 101.48 10.65 93 59027 289707 55943240
Application site rash 101.46 10.65 50 59070 2373 56230574
Pericarditis 100.58 10.65 3 59117 108920 56124027
Fluid retention 98.82 10.65 192 58928 53886 56179061
Application site pruritus 98.32 10.65 57 59063 3762 56229185
Maternal exposure during pregnancy 95.10 10.65 40 59080 189513 56043434
Alopecia 93.77 10.65 102 59018 293356 55939591
Nephrogenic systemic fibrosis 87.60 10.65 56 59064 4409 56228538
Product adhesion issue 84.92 10.65 55 59065 4428 56228519
Cerebrovascular accident 84.82 10.65 263 58857 99007 56133940
Infusion related reaction 84.48 10.65 58 59062 208873 56024074
Poisoning 81.51 10.65 83 59037 12730 56220217
Sinus bradycardia 81.00 10.65 85 59035 13501 56219446
Neovascularisation 80.30 10.65 33 59087 1016 56231931
Hypotension 78.89 10.65 491 58629 250017 55982930
Wound 78.61 10.65 24 59096 138780 56094167
Upper respiratory tract infection 75.50 10.65 204 58916 71084 56161863
Hypertensive encephalopathy 75.49 10.65 27 59093 564 56232383
Application site erythema 74.04 10.65 51 59069 4549 56228398
Body tinea 73.81 10.65 34 59086 1386 56231561
Accidental exposure to product by child 70.23 10.65 31 59089 1142 56231805
Abdominal discomfort 68.69 10.65 116 59004 277158 55955789
Swelling 67.40 10.65 92 59028 239679 55993268
Helicobacter infection 64.26 10.65 3 59117 73265 56159682
Withdrawal hypertension 64.15 10.65 17 59103 121 56232826
Rash 62.50 10.65 286 58834 492761 55740186
Constipation 61.77 10.65 393 58727 201550 56031397
Therapeutic product effect decreased 60.90 10.65 53 59067 169399 56063548
Paradoxical drug reaction 60.66 10.65 42 59078 3778 56229169
Discomfort 60.48 10.65 37 59083 141724 56091223
Application site irritation 60.12 10.65 31 59089 1621 56231326
Duodenal ulcer perforation 59.29 10.65 3 59117 68339 56164608
Inhibitory drug interaction 57.74 10.65 34 59086 2310 56230637
Sedation 55.61 10.65 117 59003 34737 56198210
Infection susceptibility increased 52.36 10.65 34 59086 2749 56230198
Chronic kidney disease 50.31 10.65 126 58994 41930 56191017
Myocardial infarction 50.24 10.65 212 58908 92658 56140289
Somnolence 48.70 10.65 316 58804 163097 56069850
Acute motor-sensory axonal neuropathy 47.74 10.65 16 59104 273 56232674
Malignant catatonia 45.50 10.65 14 59106 179 56232768
Arthralgia 44.72 10.65 326 58794 501343 55731604
Unresponsive to stimuli 44.37 10.65 101 59019 31624 56201323
Withdrawal syndrome 43.19 10.65 73 59047 18389 56214558
Intestinal angioedema 41.88 10.65 18 59102 621 56232326
Glucose tolerance impaired 41.24 10.65 39 59081 5466 56227481
Toxicity to various agents 41.20 10.65 388 58732 224176 56008771
Malignant hypertension 40.22 10.65 21 59099 1127 56231820
Lower respiratory tract infection 39.91 10.65 37 59083 114757 56118190
Contraindicated product administered 39.89 10.65 85 59035 186201 56046746
Neutropenia 39.28 10.65 66 59054 158101 56074846
Hypothermia 38.48 10.65 56 59064 12414 56220533
Nodal rhythm 38.45 10.65 23 59097 1608 56231339
Cardiac arrest 38.41 10.65 186 58934 86128 56146819
Skin induration 38.37 10.65 29 59091 2989 56229958
Peritonitis bacterial 38.29 10.65 35 59085 4698 56228249
Impaired healing 37.96 10.65 22 59098 86819 56146128
Left ventricular hypertrophy 36.75 10.65 35 59085 4949 56227998
Acute myocardial infarction 36.28 10.65 91 59029 30302 56202645
Product substitution issue 35.86 10.65 59 59061 14540 56218407
C-reactive protein increased 35.74 10.65 19 59101 78665 56154282
Anti-neutrophil cytoplasmic antibody positive vasculitis 35.48 10.65 26 59094 2557 56230390
Sleep disorder due to general medical condition, insomnia type 34.37 10.65 3 59117 43335 56189612
Respiratory arrest 33.78 10.65 89 59031 30536 56202411
Miosis 33.63 10.65 38 59082 6554 56226393
Coronary artery disease 33.46 10.65 89 59031 30707 56202240
Blister 33.45 10.65 39 59081 108848 56124099
Irritable bowel syndrome 33.42 10.65 15 59105 68443 56164504
Condition aggravated 33.20 10.65 219 58901 344679 55888268
Infection 32.45 10.65 105 59015 200101 56032846
Rheumatoid arthritis 32.44 10.65 252 58868 382352 55850595
Back pain 31.89 10.65 385 58735 236785 55996162
Nasopharyngitis 31.72 10.65 122 58998 220837 56012110
Drug ineffective 31.22 10.65 732 58388 918257 55314690
Febrile neutropenia 31.15 10.65 39 59081 105506 56127441
Gastrointestinal disorder 30.87 10.65 44 59076 112658 56120289
Lethargy 30.63 10.65 121 58999 51320 56181627
Asthma 30.53 10.65 213 58907 112557 56120390
Cardio-respiratory arrest 29.68 10.65 126 58994 55195 56177752
Medical device site pain 29.66 10.65 10 59110 174 56232773
Anuria 29.52 10.65 48 59072 11712 56221235
Malignant neoplasm progression 28.95 10.65 21 59099 73566 56159381
Skin hypertrophy 28.47 10.65 25 59095 3185 56229762
Anaesthesia 28.39 10.65 12 59108 397 56232550
Psoriatic arthropathy 27.99 10.65 22 59098 73986 56158961
Sinusitis 27.77 10.65 110 59010 197471 56035476
Urinary incontinence 27.70 10.65 81 59039 29504 56203443
Basal ganglion degeneration 27.34 10.65 12 59108 436 56232511
Hyperlipidaemia 26.83 10.65 59 59061 18050 56214897
Drug ineffective for unapproved indication 26.65 10.65 73 59047 25620 56207327
Tissue infiltration 26.48 10.65 13 59107 612 56232335
Extrapyramidal disorder 26.48 10.65 47 59073 12309 56220638
Abortion spontaneous 25.79 10.65 7 59113 43746 56189201
Accidental overdose 25.20 10.65 62 59058 20399 56212548
Respiratory moniliasis 25.12 10.65 9 59111 189 56232758
Agitation 25.10 10.65 121 58999 55915 56177032
Impaired quality of life 24.63 10.65 37 59083 8437 56224510
Drug dependence 24.36 10.65 65 59055 22468 56210479
Interstitial lung disease 24.17 10.65 15 59105 57048 56175899
Retrograde amnesia 24.07 10.65 11 59109 440 56232507
Encephalomalacia 24.03 10.65 11 59109 442 56232505
Medication error 23.15 10.65 97 59023 42238 56190709
Apnoea 23.04 10.65 33 59087 7209 56225738
Blood aldosterone increased 22.60 10.65 8 59112 162 56232785
Suspected suicide 22.12 10.65 28 59092 5438 56227509
Purpura 21.67 10.65 39 59081 10323 56222624
Hypertensive emergency 21.62 10.65 16 59104 1597 56231350
Primary hyperaldosteronism 21.60 10.65 6 59114 52 56232895
Mobility decreased 21.31 10.65 45 59075 98946 56134001
Pulse absent 20.98 10.65 26 59094 4941 56228006
Intentional product use issue 20.92 10.65 46 59074 99687 56133260
Skin disorder 20.88 10.65 68 59052 26241 56206706
Application site pain 20.69 10.65 23 59097 3897 56229050
Liver injury 20.69 10.65 9 59111 41839 56191108
Musculoskeletal stiffness 20.58 10.65 89 59031 155918 56077029
Norepinephrine increased 20.57 10.65 6 59114 63 56232884
Application site papules 20.49 10.65 6 59114 64 56232883
Pyrexia 20.48 10.65 313 58807 418460 55814487
Implant site extravasation 20.46 10.65 10 59110 466 56232481
Erythema 20.44 10.65 252 58868 155687 56077260
Atrioventricular block second degree 19.86 10.65 22 59098 3714 56229233
Medical device site discharge 19.46 10.65 5 59115 31 56232916
Renal failure 19.28 10.65 189 58931 110311 56122636
Leukopenia 19.12 10.65 28 59092 70912 56162035
Implant site infection 19.02 10.65 12 59108 923 56232024
Respiratory depression 18.97 10.65 41 59079 12394 56220553
Poor quality sleep 18.97 10.65 51 59069 17704 56215243
Pulmonary renal syndrome 18.85 10.65 9 59111 398 56232549
Off label use 18.78 10.65 443 58677 555737 55677210
Uterine enlargement 18.77 10.65 13 59107 1170 56231777
Application site discolouration 18.76 10.65 11 59109 741 56232206
Arthritis 18.61 10.65 49 59071 99803 56133144
Osteonecrosis of jaw 18.45 10.65 6 59114 33352 56199595
Gastrointestinal tract mucosal pigmentation 18.39 10.65 10 59110 583 56232364
Coma scale abnormal 18.25 10.65 24 59096 4839 56228108
Cerebral ischaemia 18.08 10.65 27 59093 6123 56226824
Inguinal hernia 18.03 10.65 15 59105 1776 56231171
Renin decreased 17.92 10.65 6 59114 102 56232845
Page kidney 17.91 10.65 4 59116 12 56232935
Anhedonia 17.85 10.65 35 59085 9879 56223068
Vascular stenosis 17.82 10.65 8 59112 307 56232640
Injection site erythema 17.70 10.65 34 59086 77414 56155533
Aggression 17.58 10.65 57 59063 21949 56210998
Pernicious anaemia 17.53 10.65 10 59110 640 56232307
Hypertrichosis 17.36 10.65 12 59108 1076 56231871
Application site vesicles 17.10 10.65 13 59107 1352 56231595
Hyperlactacidaemia 16.89 10.65 17 59103 2571 56230376
Tremor 16.87 10.65 198 58922 120891 56112056
Renal transplant failure 16.87 10.65 10 59110 688 56232259
Hepatotoxicity 16.55 10.65 6 59114 31147 56201800
Blood pressure abnormal 16.41 10.65 41 59079 13619 56219328
Seizure 16.30 10.65 202 58918 124917 56108030
Focal segmental glomerulosclerosis 16.28 10.65 13 59107 1453 56231494
Posterior reversible encephalopathy syndrome 16.21 10.65 45 59075 15915 56217032
Bone density decreased 16.07 10.65 39 59081 12721 56220226
Diarrhoea 16.06 10.65 530 58590 637977 55594970
Dialysis 15.97 10.65 33 59087 9669 56223278
White blood cell count decreased 15.93 10.65 73 59047 125917 56107030
Cardiac hypertrophy 15.78 10.65 11 59109 1000 56231947
Medical device site erythema 15.68 10.65 4 59116 24 56232923
Normochromic normocytic anaemia 15.61 10.65 21 59099 4328 56228619
Tachyphylaxis 15.58 10.65 7 59113 269 56232678
Arteriospasm coronary 15.26 10.65 19 59101 3628 56229319
Hip arthroplasty 15.22 10.65 11 59109 38612 56194335
Human ehrlichiosis 15.20 10.65 6 59114 166 56232781
Hyperaesthesia 14.91 10.65 30 59090 8627 56224320
Ill-defined disorder 14.88 10.65 31 59089 68512 56164435
Blood glucose increased 14.84 10.65 132 58988 75019 56157928
Gamma-glutamyltransferase increased 14.81 10.65 7 59113 30998 56201949
Device infusion issue 14.78 10.65 13 59107 1659 56231288
Sinus arrhythmia 14.73 10.65 12 59108 1379 56231568
Loss of personal independence in daily activities 14.36 10.65 41 59079 81328 56151619
Neutrophil count decreased 14.09 10.65 19 59101 49803 56183144
End stage renal disease 14.08 10.65 24 59096 6087 56226860
Patent ductus arteriosus 14.06 10.65 19 59101 3932 56229015
Treatment failure 14.04 10.65 113 59007 170279 56062668
Product quality issue 13.83 10.65 68 59052 31668 56201279
Systolic dysfunction 13.74 10.65 12 59108 1518 56231429
Product use issue 13.72 10.65 127 58993 185914 56047033
Trichoglossia 13.52 10.65 6 59114 224 56232723
Klebsiella infection 13.50 10.65 27 59093 7729 56225218
Intercepted medication error 13.47 10.65 8 59112 552 56232395
Product tampering 13.47 10.65 6 59114 226 56232721
Knee arthroplasty 13.43 10.65 16 59104 44243 56188704
Left ventricular failure 13.37 10.65 21 59099 4975 56227972
Depressed level of consciousness 13.21 10.65 103 59017 56330 56176617
Emotional distress 13.13 10.65 64 59056 29699 56203248
Delirium 13.12 10.65 83 59037 42434 56190513
Psychogenic seizure 12.96 10.65 12 59108 1637 56231310
SJS-TEN overlap 12.90 10.65 6 59114 250 56232697
Injection site abscess 12.85 10.65 10 59110 1076 56231871
Fibrosis 12.78 10.65 18 59102 3873 56229074
Neoplasm progression 12.77 10.65 9 59111 32007 56200940
Hypertensive heart disease 12.70 10.65 14 59106 2349 56230598
Hypernatraemia 12.69 10.65 24 59096 6596 56226351
Disease progression 12.67 10.65 62 59058 105111 56127836
Osteoporosis 12.65 10.65 22 59098 52030 56180917
Akathisia 12.60 10.65 28 59092 8624 56224323
Spinal pain 12.56 10.65 34 59086 11850 56221097
Skin fibrosis 12.56 10.65 9 59111 855 56232092
Anxiety 12.50 10.65 278 58842 192894 56040053
Colitis ulcerative 12.45 10.65 5 59115 24386 56208561
Kidney fibrosis 12.40 10.65 12 59108 1730 56231217
Pulmonary fibrosis 12.36 10.65 8 59112 29750 56203197
Exposure via ingestion 12.35 10.65 15 59105 2793 56230154
Dry mouth 12.28 10.65 112 59008 64093 56168854
Left atrial dilatation 12.26 10.65 12 59108 1754 56231193
Hepatic function abnormal 12.17 10.65 11 59109 34547 56198400
Psoriasis 12.14 10.65 53 59067 92639 56140308
Drug abuser 12.13 10.65 15 59105 2844 56230103
Injection site pruritus 11.85 10.65 16 59104 41915 56191032
Drug detoxification 11.81 10.65 5 59115 166 56232781
Hypervolaemia 11.75 10.65 57 59063 26401 56206546
Adulterated product 11.69 10.65 4 59116 73 56232874
Monoplegia 11.66 10.65 15 59105 2959 56229988
Pain in jaw 11.59 10.65 15 59105 40021 56192926
Device expulsion 11.57 10.65 9 59111 30440 56202507
Parosmia 11.51 10.65 19 59101 4692 56228255
Implant site haematoma 11.49 10.65 4 59116 77 56232870
Tic 11.47 10.65 10 59110 1261 56231686
Drug reaction with eosinophilia and systemic symptoms 11.46 10.65 9 59111 30295 56202652
Hepatic cirrhosis 11.46 10.65 4 59116 21259 56211688
Alanine aminotransferase increased 11.41 10.65 55 59065 93607 56139340
Daydreaming 11.40 10.65 6 59114 327 56232620
Fanconi syndrome 11.39 10.65 10 59110 1273 56231674
Enterococcal infection 11.32 10.65 24 59096 7160 56225787
Chest pain 11.31 10.65 270 58850 189527 56043420
Application site haematoma 11.24 10.65 3 59117 22 56232925
Renal cyst 11.24 10.65 28 59092 9281 56223666
Femur fracture 11.09 10.65 15 59105 39280 56193667
Medical device site swelling 11.01 10.65 3 59117 24 56232923
Steroid diabetes 10.99 10.65 9 59111 1042 56231905
Impaired work ability 10.97 10.65 37 59083 14535 56218412
Peripheral swelling 10.92 10.65 177 58943 234549 55998398
Glomerulonephritis 10.88 10.65 11 59109 1672 56231275
Labile blood pressure 10.83 10.65 11 59109 1682 56231265
Product complaint 10.82 10.65 32 59088 11728 56221219
Drug dependence, antepartum 10.80 10.65 3 59117 26 56232921
Joint contracture 10.78 10.65 11 59109 1691 56231256
Acute kidney injury 10.78 10.65 330 58790 240433 55992514

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 226.40 10.95 409 39372 91105 31566458
Drug withdrawal syndrome 203.98 10.95 177 39604 18573 31638990
Hypertension 155.72 10.95 431 39350 127669 31529894
Aggression 150.89 10.95 209 39572 37082 31620481
Bradycardia 135.92 10.95 281 39500 69046 31588517
Withdrawal hypertension 128.10 10.95 33 39748 168 31657395
Respiratory depression 113.43 10.95 114 39667 14396 31643167
Hypertensive crisis 94.01 10.95 80 39701 8167 31649396
Drug dependence 87.49 10.95 124 39657 22455 31635108
Victim of child abuse 79.09 10.95 33 39748 879 31656684
Oppositional defiant disorder 76.98 10.95 28 39753 510 31657053
Decreased eye contact 72.03 10.95 26 39755 463 31657100
Application site rash 70.40 10.95 29 39752 747 31656816
Choreoathetosis 68.71 10.95 31 39750 1002 31656561
Withdrawal syndrome 68.58 10.95 79 39702 11638 31645925
Blood pressure inadequately controlled 65.43 10.95 40 39741 2429 31655134
Agitation 63.41 10.95 180 39601 53989 31603574
Accidental exposure to product by child 63.36 10.95 33 39748 1469 31656094
Febrile neutropenia 62.18 10.95 38 39743 121811 31535752
Blood pressure increased 61.86 10.95 230 39551 79403 31578160
Sedation 61.75 10.95 96 39685 18869 31638694
Sinus bradycardia 60.08 10.95 75 39706 12012 31645551
Anxiety 57.91 10.95 247 39534 90786 31566777
Miosis 57.40 10.95 62 39719 8508 31649055
Dystonia 54.95 10.95 66 39715 10159 31647404
Product substitution issue 54.20 10.95 63 39718 9369 31648194
Hypotension 54.15 10.95 440 39341 204178 31453385
Cardiac failure congestive 53.29 10.95 219 39562 79168 31578395
Mental status changes 49.59 10.95 127 39654 35841 31621722
Crying 49.38 10.95 47 39734 5550 31652013
Trismus 48.96 10.95 33 39748 2372 31655191
Somnolence 47.98 10.95 249 39532 99196 31558367
Psychomotor hyperactivity 47.68 10.95 57 39724 8730 31648833
Bruxism 47.32 10.95 28 39753 1602 31655961
Homicidal ideation 46.73 10.95 33 39748 2558 31655005
Hypertensive emergency 45.64 10.95 23 39758 955 31656608
Product adhesion issue 43.75 10.95 26 39755 1499 31656064
Overweight 42.84 10.95 26 39755 1558 31656005
Nephrogenic systemic fibrosis 42.30 10.95 37 39744 3918 31653645
Obesity 41.57 10.95 60 39721 11040 31646523
Serotonin syndrome 41.40 10.95 80 39701 18693 31638870
Cerebrovascular accident 41.12 10.95 203 39578 79281 31578282
Interstitial lung disease 40.98 10.95 13 39768 61390 31596173
Neutropenia 40.78 10.95 71 39710 140293 31517270
Suicidal ideation 40.67 10.95 119 39662 36287 31621276
Blood prolactin increased 39.72 10.95 25 39756 1599 31655964
Lethargy 39.12 10.95 122 39659 38519 31619044
Tic 38.25 10.95 26 39755 1895 31655668
Epidural lipomatosis 38.24 10.95 19 39762 765 31656798
Cardiac arrest 38.21 10.95 216 39565 88846 31568717
Irritability 38.17 10.95 87 39694 22802 31634761
Pyrexia 37.94 10.95 225 39556 303615 31353948
Dyskinesia 36.57 10.95 81 39700 20829 31636734
Catatonia 36.11 10.95 37 39744 4777 31652786
Malignant catatonia 36.04 10.95 13 39768 231 31657332
Device failure 35.90 10.95 26 39755 2097 31655466
Pneumonia 35.47 10.95 261 39520 335051 31322512
Peritonitis bacterial 35.16 10.95 40 39741 5812 31651751
Thrombocytopenia 34.78 10.95 80 39701 142667 31514896
Application site pruritus 34.14 10.95 21 39760 1289 31656274
Rheumatoid arthritis 33.96 10.95 9 39772 47800 31609763
Aplastic anaemia 33.38 10.95 49 39732 9154 31648409
Respiratory arrest 32.42 10.95 89 39692 26168 31631395
Hepatic function abnormal 30.76 10.95 7 39774 41215 31616348
Toxicity to various agents 30.52 10.95 355 39426 181132 31476431
Hypotonia 30.35 10.95 41 39740 7092 31650471
Autonomic nervous system imbalance 30.32 10.95 25 39756 2442 31655121
Application site erythema 29.19 10.95 23 39758 2106 31655457
Neuroleptic malignant syndrome 29.11 10.95 65 39716 16804 31640759
Hyperaesthesia 28.97 10.95 30 39751 3921 31653642
Malignant neoplasm progression 28.81 10.95 34 39747 78964 31578599
Product prescribing error 28.79 10.95 71 39710 19571 31637992
Unresponsive to stimuli 28.49 10.95 84 39697 25716 31631847
Tardive dyskinesia 28.43 10.95 35 39746 5524 31652039
Pancytopenia 28.34 10.95 41 39740 87275 31570288
Intestinal pseudo-obstruction 28.18 10.95 20 39761 1563 31656000
Suspected suicide 28.00 10.95 30 39751 4077 31653486
Emotional distress 27.85 10.95 58 39723 14298 31643265
Child abuse 27.34 10.95 12 39769 363 31657200
Application site irritation 26.72 10.95 14 39767 631 31656932
Affect lability 26.66 10.95 27 39754 3438 31654125
Accelerated hypertension 24.82 10.95 10 39771 243 31657320
Inadequate analgesia 24.49 10.95 23 39758 2670 31654893
Juvenile idiopathic arthritis 24.36 10.95 19 39762 1714 31655849
Toxic epidermal necrolysis 23.92 10.95 66 39715 19458 31638105
Kidney transplant rejection 23.89 10.95 37 39744 7245 31650318
Accidental overdose 23.45 10.95 63 39718 18287 31639276
Natural killer cell count decreased 22.73 10.95 4 39777 0 31657563
Poisoning 22.56 10.95 44 39737 10347 31647216
Injury 22.56 10.95 65 39716 19644 31637919
Insomnia 22.39 10.95 199 39582 94637 31562926
Paradoxical drug reaction 21.59 10.95 23 39758 3106 31654457
Corneal reflex decreased 21.21 10.95 8 39773 162 31657401
Hyperkinesia 20.66 10.95 17 39764 1656 31655907
Anger 20.40 10.95 44 39737 11109 31646454
Abnormal behaviour 20.32 10.95 71 39710 23757 31633806
Prostate cancer 20.19 10.95 11 39770 37590 31619973
Overdose 20.16 10.95 178 39603 84486 31573077
Drug tolerance 20.01 10.95 20 39761 2507 31655056
Galactorrhoea 19.94 10.95 10 39771 411 31657152
Coordination abnormal 19.92 10.95 34 39747 7217 31650346
Drug ineffective for unapproved indication 19.71 10.95 58 39723 17732 31639831
Product administered to patient of inappropriate age 19.71 10.95 21 39760 2836 31654727
Speech disorder 19.68 10.95 71 39710 24130 31633433
Diarrhoea 19.24 10.95 319 39462 352090 31305473
Medical device site pain 19.10 10.95 6 39775 68 31657495
Labile hypertension 19.02 10.95 6 39775 69 31657494
Fibrosis 18.95 10.95 19 39762 2390 31655173
Axillary pain 18.28 10.95 9 39772 355 31657208
Platelet count decreased 18.22 10.95 74 39707 110361 31547202
General physical health deterioration 18.10 10.95 77 39704 113358 31544205
Tourette's disorder 18.08 10.95 6 39775 82 31657481
Drug screen positive 17.71 10.95 23 39758 3829 31653734
Mood altered 17.71 10.95 35 39746 8311 31649252
Implant site extravasation 17.65 10.95 9 39772 383 31657180
Metabolic alkalosis 17.47 10.95 14 39767 1313 31656250
Respiratory rate decreased 17.29 10.95 17 39764 2088 31655475
Accidental poisoning 17.24 10.95 11 39770 720 31656843
Attention deficit hyperactivity disorder 17.21 10.95 18 39763 2380 31655183
Neutrophil count decreased 16.87 10.95 20 39761 46374 31611189
Anhedonia 16.75 10.95 32 39749 7410 31650153
Loss of consciousness 16.57 10.95 159 39622 77196 31580367
Reaction to excipient 16.41 10.95 9 39772 445 31657118
Brief psychotic disorder with marked stressors 16.16 10.95 7 39774 205 31657358
Streptococcal infection 16.11 10.95 24 39757 4543 31653020
Device infusion issue 16.09 10.95 10 39771 625 31656938
Poor quality sleep 16.05 10.95 32 39749 7646 31649917
Pain 16.05 10.95 326 39455 186433 31471130
Device power source issue 15.97 10.95 8 39773 328 31657235
Oromandibular dystonia 15.84 10.95 9 39772 477 31657086
Cardio-respiratory arrest 15.71 10.95 115 39666 51611 31605952
Inflammation 15.70 10.95 6 39775 25235 31632328
Hyperhidrosis 15.68 10.95 141 39640 67252 31590311
Transcription medication error 15.62 10.95 6 39775 128 31657435
Psoriatic arthropathy 15.61 10.95 3 39778 19880 31637683
Contraindicated product administered 15.48 10.95 3 39778 19769 31637794
Mast cell degranulation present 15.44 10.95 5 39776 63 31657500
Product prescribing issue 15.26 10.95 14 39767 1577 31655986
Drooling 15.05 10.95 19 39762 3076 31654487
Double inlet left ventricle 14.97 10.95 4 39777 24 31657539
Product compounding quality issue 14.84 10.95 4 39777 25 31657538
Myocardial infarction 14.83 10.95 212 39569 113242 31544321
Infection 14.73 10.95 53 39728 81878 31575685
Saccadic eye movement 14.58 10.95 6 39775 154 31657409
Cardiac failure 14.55 10.95 57 39724 85896 31571667
Metastases to eye 14.52 10.95 5 39776 77 31657486
Renal transplant 14.48 10.95 14 39767 1685 31655878
Autoimmune enteropathy 14.45 10.95 4 39777 28 31657535
Gastrointestinal tract mucosal pigmentation 14.32 10.95 8 39773 410 31657153
Hypoxic-ischaemic encephalopathy 14.16 10.95 22 39759 4319 31653244
Lower respiratory tract infection 14.11 10.95 9 39772 28228 31629335
Skin tightness 14.06 10.95 15 39766 2029 31655534
Skin induration 13.95 10.95 15 39766 2047 31655516
Productive cough 13.83 10.95 13 39768 33527 31624036
Pneumocystis jirovecii pneumonia 13.81 10.95 3 39778 18248 31639315
Post transplant distal limb syndrome 13.77 10.95 7 39774 296 31657267
End stage renal disease 13.71 10.95 31 39750 8078 31649485
Incision site pain 13.58 10.95 14 39767 1820 31655743
Univentricular heart 13.56 10.95 4 39777 36 31657527
Disease progression 13.46 10.95 63 39718 90401 31567162
Intentional self-injury 13.43 10.95 42 39739 13273 31644290
Skin hypertrophy 13.39 10.95 16 39765 2449 31655114
Product preparation issue 13.37 10.95 7 39774 315 31657248
Sprue-like enteropathy 13.32 10.95 8 39773 470 31657093
Gastric hypomotility 13.27 10.95 5 39776 101 31657462
Therapeutic response decreased 13.19 10.95 67 39714 26442 31631121
Hydrocele male infected 13.19 10.95 4 39777 40 31657523
Drug withdrawal maintenance therapy 13.09 10.95 5 39776 105 31657458
Sepsis 12.95 10.95 125 39656 151804 31505759
White blood cell count decreased 12.93 10.95 61 39720 87337 31570226
Harlequin syndrome 12.90 10.95 3 39778 9 31657554
Drug ineffective 12.89 10.95 613 39168 394960 31262603
C-reactive protein increased 12.88 10.95 26 39755 48624 31608939
Impaired gastric emptying 12.83 10.95 18 39763 3226 31654337
Posterior reversible encephalopathy syndrome 12.82 10.95 33 39748 9334 31648229
Hypercapnia 12.78 10.95 20 39761 3951 31653612
Impulsive behaviour 12.50 10.95 14 39767 1999 31655564
Cardiomyopathy 12.48 10.95 45 39736 15288 31642275
Intentional product misuse 12.47 10.95 86 39695 37865 31619698
Labelled drug-drug interaction issue 12.40 10.95 6 39775 228 31657335
Electrocardiogram PR prolongation 12.31 10.95 9 39772 737 31656826
Colitis ulcerative 12.22 10.95 4 39777 18525 31639038
Cytomegalovirus infection 12.18 10.95 8 39773 24699 31632864
Atrioventricular block first degree 12.10 10.95 24 39757 5713 31651850
Pulmonary embolism 12.06 10.95 57 39724 81589 31575974
Product quality issue 12.04 10.95 46 39735 16065 31641498
Hyponatraemia 11.82 10.95 50 39731 73749 31583814
Rash maculo-papular 11.79 10.95 9 39772 25710 31631853
Tremor 11.72 10.95 147 39634 76273 31581290
Nervousness 11.70 10.95 37 39744 11763 31645800
Nephropathy 11.65 10.95 23 39758 5456 31652107
COVID-19 11.57 10.95 33 39748 54788 31602775
Drug withdrawal headache 11.53 10.95 3 39778 16 31657547
Cancer pain 11.45 10.95 15 39766 2518 31655045
Lymphocele 11.37 10.95 11 39770 1325 31656238
Product use issue 11.34 10.95 115 39666 56644 31600919
Chronic kidney disease 11.28 10.95 84 39697 37891 31619672
Muscle spasticity 11.20 10.95 23 39758 5612 31651951
Alopecia 11.19 10.95 6 39775 20689 31636874
Hyperbilirubinaemia 11.11 10.95 3 39778 15747 31641816
Septic shock 11.11 10.95 44 39737 66114 31591449
Hepatitis 11.07 10.95 7 39774 22059 31635504
Mood swings 11.05 10.95 27 39754 7397 31650166
Radicular pain 11.04 10.95 4 39777 72 31657491
Disseminated intravascular coagulation 11.03 10.95 6 39775 20531 31637032
Drug resistance 11.02 10.95 8 39773 23445 31634118

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 562.43 10.36 970 81114 226165 70620195
Temperature regulation disorder 334.44 10.36 142 81942 4302 70842058
Drug withdrawal syndrome 328.53 10.36 285 81799 32430 70813930
Hypertension 322.56 10.36 909 81175 295124 70551236
Bradycardia 281.76 10.36 512 81572 124103 70722257
Hypertensive crisis 235.32 10.36 188 81896 19074 70827286
Food allergy 233.41 10.36 137 81947 8387 70837973
Coeliac disease 228.63 10.36 138 81946 8895 70837465
Cardiac failure congestive 182.88 10.36 451 81633 135006 70711354
Withdrawal hypertension 173.89 10.36 47 82037 326 70846034
Mental status changes 173.66 10.36 283 81801 62818 70783542
Immunodeficiency 160.38 10.36 145 81939 17410 70828950
Aggression 155.17 10.36 233 81851 48213 70798147
Bursitis 154.45 10.36 172 81912 26501 70819859
Sinus bradycardia 144.87 10.36 157 81927 23466 70822894
Accidental exposure to product by child 139.07 10.36 67 82017 2739 70843621
Overdose 136.04 10.36 469 81615 169276 70677084
Hyperhidrosis 133.18 10.36 394 81690 131192 70715168
Respiratory depression 123.40 10.36 148 81936 24683 70821677
Synovitis 115.38 10.36 9 82075 129219 70717141
Cerebrovascular accident 114.57 10.36 396 81688 143074 70703286
Poisoning 104.58 10.36 130 81954 22492 70823868
Hypotension 103.07 10.36 810 81274 403571 70442789
Withdrawal syndrome 100.81 10.36 134 81950 24770 70821590
Miosis 97.65 10.36 100 81984 14001 70832359
Sedation 90.62 10.36 180 81904 46551 70799809
Drug dependence 90.19 10.36 158 81926 37163 70809197
Blood pressure inadequately controlled 89.15 10.36 64 82020 5528 70840832
Joint swelling 87.93 10.36 98 81986 253113 70593247
Somnolence 87.87 10.36 486 81598 215120 70631240
Toxicity to various agents 86.32 10.36 745 81339 381427 70464933
Cardiac arrest 83.17 10.36 386 81698 159448 70686912
Oppositional defiant disorder 81.42 10.36 28 82056 468 70845892
Victim of child abuse 80.77 10.36 33 82051 905 70845455
Malignant catatonia 80.13 10.36 27 82057 423 70845937
Arthropathy 79.56 10.36 37 82047 150020 70696340
Paradoxical drug reaction 79.40 10.36 64 82020 6572 70839788
Neutropenia 79.34 10.36 109 81975 257047 70589313
Febrile neutropenia 77.82 10.36 73 82011 204245 70642115
Agitation 74.73 10.36 258 81826 93117 70753243
Neovascularisation 74.43 10.36 33 82051 1112 70845248
Blood pressure increased 74.17 10.36 421 81663 188096 70658264
Respiratory arrest 73.15 10.36 180 81904 53753 70792607
Nephrogenic systemic fibrosis 71.63 10.36 58 82026 5994 70840366
Alopecia 70.91 10.36 75 82009 198415 70647945
Hypertensive encephalopathy 68.15 10.36 29 82055 883 70845477
Lethargy 67.40 10.36 216 81868 75034 70771326
Rash erythematous 67.39 10.36 170 81914 51548 70794812
Drug intolerance 67.28 10.36 98 81986 225589 70620771
Infusion related reaction 65.80 10.36 79 82005 197455 70648905
Body tinea 65.46 10.36 32 82052 1351 70845009
Pericarditis 65.25 10.36 10 82074 84695 70761665
Glossodynia 64.85 10.36 11 82073 86476 70759884
Fluid retention 64.27 10.36 190 81894 63195 70783165
Interstitial lung disease 61.68 10.36 22 82062 104663 70741697
Myocardial infarction 60.85 10.36 373 81711 171272 70675088
Hypertensive emergency 60.71 10.36 37 82047 2426 70843934
Decreased eye contact 60.36 10.36 26 82058 816 70845544
Choreoathetosis 59.79 10.36 31 82053 1485 70844875
Rash 58.47 10.36 349 81735 510213 70336147
Arthralgia 56.12 10.36 347 81737 503043 70343317
Unresponsive to stimuli 55.85 10.36 159 81925 51772 70794588
Systemic lupus erythematosus 55.77 10.36 24 82060 101878 70744482
Malignant neoplasm progression 54.48 10.36 37 82047 121702 70724658
Upper respiratory tract infection 54.08 10.36 208 81876 79066 70767294
Application site pruritus 52.39 10.36 39 82045 3562 70842798
Helicobacter infection 52.23 10.36 3 82081 55653 70790707
Pyrexia 50.66 10.36 454 81630 606498 70239862
Homicidal ideation 50.62 10.36 37 82047 3286 70843074
Maternal exposure during pregnancy 50.37 10.36 36 82048 115309 70731051
Anxiety 49.88 10.36 430 81654 219900 70626460
Infection susceptibility increased 49.81 10.36 35 82049 2922 70843438
Accidental overdose 49.52 10.36 119 81965 35002 70811358
Suspected suicide 49.47 10.36 56 82028 8778 70837582
Medical device site pain 47.70 10.36 16 82068 247 70846113
Application site irritation 46.94 10.36 27 82057 1590 70844770
Application site rash 46.51 10.36 29 82055 1980 70844380
Cardio-respiratory arrest 45.77 10.36 234 81850 100443 70745917
Wound 45.54 10.36 29 82055 98703 70747657
Lower respiratory tract infection 44.97 10.36 38 82046 111875 70734485
Trismus 44.44 10.36 41 82043 5050 70841310
Drug ineffective for unapproved indication 44.40 10.36 121 81963 38417 70807943
Duodenal ulcer perforation 44.39 10.36 4 82080 51108 70795252
Diarrhoea 44.15 10.36 640 81444 782701 70063659
Inhibitory drug interaction 41.95 10.36 35 82049 3772 70842588
Swelling 41.84 10.36 98 81986 188441 70657919
Peritonitis bacterial 41.20 10.36 52 82032 9132 70837228
Irritability 41.07 10.36 117 81967 38108 70808252
Psoriatic arthropathy 41.00 10.36 12 82072 64759 70781601
Therapeutic product effect decreased 40.76 10.36 64 82020 142954 70703406
Acute motor-sensory axonal neuropathy 40.47 10.36 16 82068 402 70845958
Apnoea 40.46 10.36 56 82028 10753 70835607
Dystonia 39.52 10.36 77 82007 19629 70826731
Infection 38.90 10.36 120 81964 210665 70635695
Hepatic function abnormal 38.85 10.36 15 82069 67981 70778379
C-reactive protein increased 38.07 10.36 43 82041 110474 70735886
Crying 37.94 10.36 79 82005 21120 70825240
Nasopharyngitis 37.90 10.36 131 81953 222075 70624285
Poor quality sleep 37.79 10.36 77 82007 20272 70826088
Condition aggravated 36.44 10.36 318 81766 427317 70419043
Catatonia 36.41 10.36 46 82038 8087 70838273
Tic 36.23 10.36 28 82056 2705 70843655
Glucose tolerance impaired 36.18 10.36 42 82042 6764 70839596
Medication error 36.12 10.36 146 81938 56766 70789594
Epidural lipomatosis 36.11 10.36 19 82065 938 70845422
Psychomotor hyperactivity 35.56 10.36 64 82020 15369 70830991
Hyperaesthesia 35.55 10.36 53 82031 10889 70835471
Product substitution issue 35.51 10.36 71 82013 18442 70827918
Intestinal angioedema 35.27 10.36 18 82066 834 70845526
Application site erythema 35.22 10.36 35 82049 4726 70841634
Coronary artery disease 35.20 10.36 155 81929 62581 70783779
Malignant hypertension 35.06 10.36 22 82062 1519 70844841
Constipation 34.56 10.36 445 81639 251993 70594367
Implant site extravasation 34.44 10.36 17 82067 733 70845627
Left ventricular hypertrophy 33.98 10.36 50 82034 10152 70836208
Obesity 33.83 10.36 87 81997 26684 70819676
Gastrointestinal tract mucosal pigmentation 33.09 10.36 18 82066 951 70845409
Suicidal ideation 32.49 10.36 163 81921 69433 70776927
Anti-neutrophil cytoplasmic antibody positive vasculitis 31.63 10.36 28 82056 3269 70843091
Neutrophil count decreased 31.61 10.36 30 82054 83526 70762834
Exposure during pregnancy 31.46 10.36 33 82051 87684 70758676
Impaired healing 31.44 10.36 24 82060 74350 70772010
Thrombocytopenia 31.40 10.36 156 81928 238954 70607406
Chronic kidney disease 31.38 10.36 147 81937 60910 70785450
Bruxism 30.57 10.36 29 82055 3700 70842660
Sleep disorder due to general medical condition, insomnia type 30.49 10.36 3 82081 35729 70810631
Blood prolactin increased 30.40 10.36 29 82055 3725 70842635
Discomfort 30.21 10.36 47 82037 105389 70740971
Abdominal discomfort 29.96 10.36 137 81947 214521 70631839
Kidney transplant rejection 29.19 10.36 46 82038 9915 70836445
Dyskinesia 29.02 10.36 109 81975 40965 70805395
Arthritis 28.73 10.36 43 82041 97937 70748423
Skin hypertrophy 28.66 10.36 31 82053 4621 70841739
White blood cell count decreased 28.53 10.36 101 81983 170040 70676320
Aplastic anaemia 28.41 10.36 61 82023 16655 70829705
Child abuse 28.33 10.36 12 82072 361 70845999
Emotional distress 28.22 10.36 101 81983 37087 70809273
Overweight 27.86 10.36 27 82057 3536 70842824
Irritable bowel syndrome 27.78 10.36 12 82072 50838 70795522
Posterior reversible encephalopathy syndrome 27.49 10.36 76 82008 24326 70822034
Acute myocardial infarction 27.46 10.36 161 81923 72726 70773634
Skin induration 27.12 10.36 29 82055 4266 70842094
Osteonecrosis of jaw 27.06 10.36 7 82077 40995 70805365
Product compounding quality issue 27.06 10.36 7 82077 40 70846320
Autonomic nervous system imbalance 26.88 10.36 29 82055 4310 70842050
Sinusitis 26.69 10.36 103 81981 169092 70677268
Device infusion issue 26.57 10.36 20 82064 1857 70844503
Nodal rhythm 26.28 10.36 24 82060 2917 70843443
Drug screen positive 26.09 10.36 33 82051 5807 70840553
Liver disorder 25.86 10.36 20 82064 61548 70784812
Anhedonia 25.47 10.36 53 82031 14160 70832200
Product adhesion issue 25.34 10.36 22 82062 2502 70843858
Anger 25.30 10.36 57 82027 16075 70830285
Tardive dyskinesia 25.24 10.36 43 82041 9886 70836474
Medical device site discharge 25.02 10.36 7 82077 56 70846304
Neuroleptic malignant syndrome 24.51 10.36 76 82008 25931 70820429
Intentional product misuse 24.51 10.36 167 81917 79428 70766932
Pneumocystis jirovecii pneumonia 24.47 10.36 3 82081 30079 70816281
Tremor 24.16 10.36 281 81803 155343 70691017
Loss of consciousness 24.10 10.36 281 81803 155435 70690925
Hypothermia 24.06 10.36 65 82019 20529 70825831
Pneumonia 23.66 10.36 518 81566 595714 70250646
Application site discolouration 23.48 10.36 13 82071 711 70845649
Akathisia 23.40 10.36 47 82037 12246 70834114
Intentional product use issue 23.16 10.36 67 82017 120075 70726285
Basal ganglion degeneration 23.12 10.36 11 82073 437 70845923
Oromandibular dystonia 22.94 10.36 14 82070 920 70845440
Abnormal behaviour 22.79 10.36 90 81994 34619 70811741
Intestinal pseudo-obstruction 22.77 10.36 20 82064 2310 70844050
Extrapyramidal disorder 22.76 10.36 64 82020 20686 70825674
Hyperlipidaemia 22.73 10.36 70 82014 23793 70822567
Accelerated hypertension 22.45 10.36 12 82072 612 70845748
Pulmonary fibrosis 22.38 10.36 6 82078 34304 70812056
Anaesthesia 22.27 10.36 11 82073 475 70845885
Attention deficit hyperactivity disorder 22.17 10.36 22 82062 2965 70843395
Colitis ulcerative 22.00 10.36 6 82078 33917 70812443
Bone marrow failure 21.78 10.36 15 82069 48995 70797365
Rash maculo-papular 21.76 10.36 16 82068 50529 70795831
Tissue infiltration 21.75 10.36 12 82072 652 70845708
Implant site infection 21.55 10.36 17 82067 1692 70844668
Contraindicated product administered 21.19 10.36 82 82002 134530 70711830
Prostate cancer 21.19 10.36 5 82079 31158 70815202
Retrograde amnesia 21.02 10.36 11 82073 537 70845823
Acute myeloid leukaemia 20.97 10.36 5 82079 30935 70815425
Anuria 20.96 10.36 60 82024 19593 70826767
Fibrosis 20.83 10.36 27 82057 4867 70841493
Insomnia 20.81 10.36 361 81723 217445 70628915
Renin decreased 20.52 10.36 7 82077 114 70846246
Dialysis 20.40 10.36 55 82029 17347 70829013
Product prescribing error 20.17 10.36 94 81990 38858 70807502
Leukopenia 20.12 10.36 60 82024 106500 70739860
Disease progression 20.10 10.36 103 81981 156569 70689791
Urinary incontinence 20.10 10.36 92 81992 37750 70808610
Device failure 20.02 10.36 29 82055 5806 70840554
Seizure 20.00 10.36 303 81781 177659 70668701
Inflammation 19.86 10.36 38 82046 78627 70767733
Blood aldosterone increased 19.77 10.36 8 82076 214 70846146
Primary hyperaldosteronism 19.67 10.36 7 82077 130 70846230
Reaction to excipient 19.46 10.36 15 82069 1443 70844917
Atrioventricular block second degree 19.45 10.36 31 82053 6747 70839613
Lymphopenia 19.39 10.36 4 82080 27355 70819005
Cancer pain 19.37 10.36 26 82058 4848 70841512
Back pain 19.35 10.36 430 81654 270722 70575638
Device power source issue 19.28 10.36 12 82072 817 70845543
Norepinephrine increased 19.12 10.36 6 82078 74 70846286
Drug eruption 19.05 10.36 11 82073 39485 70806875
Pancytopenia 19.02 10.36 100 81984 151007 70695353
Neutropenic sepsis 18.96 10.36 3 82081 24827 70821533
Hepatitis 18.84 10.36 18 82066 49962 70796398
Hypotonia 18.69 10.36 42 82042 11823 70834537
Neoplasm progression 18.60 10.36 15 82069 45213 70801147
Vascular stenosis 18.49 10.36 10 82074 522 70845838
Affect lability 18.37 10.36 38 82046 10108 70836252
Drug withdrawal headache 18.23 10.36 6 82078 87 70846273
Platelet count decreased 18.20 10.36 126 81958 178096 70668264
Impaired quality of life 18.07 10.36 35 82049 8881 70837479
Atrioventricular block first degree 18.03 10.36 41 82043 11632 70834728
Osteoporosis 17.99 10.36 18 82066 48889 70797471
Productive cough 17.95 10.36 40 82044 78297 70768063
Muscle contracture 17.86 10.36 17 82067 2177 70844183
Pernicious anaemia 17.77 10.36 10 82074 565 70845795
Liver injury 17.65 10.36 13 82071 41022 70805338
Infusion site mass 17.49 10.36 13 82071 1184 70845176
Psoriasis 17.47 10.36 57 82027 98376 70747984
Injection site abscess 17.41 10.36 14 82070 1432 70844928
Drug tolerance 17.36 10.36 31 82053 7397 70838963
Mood altered 17.28 10.36 50 82034 16425 70829935
Serotonin syndrome 17.16 10.36 95 81989 42019 70804341
Injection site erythema 16.90 10.36 37 82047 72887 70773473
Musculoskeletal stiffness 16.85 10.36 101 81983 147659 70698701
Basal cell carcinoma 16.81 10.36 9 82075 33689 70812671
Speech disorder 16.70 10.36 108 81976 50472 70795888
Cytomegalovirus infection 16.59 10.36 13 82071 39745 70806615
Abortion spontaneous 16.58 10.36 5 82079 26474 70819886
Product administered to patient of inappropriate age 16.51 10.36 24 82060 4819 70841541
Medical device site infection 16.48 10.36 9 82075 479 70845881
Incision site pain 16.31 10.36 18 82066 2743 70843617
Corneal reflex decreased 16.25 10.36 8 82076 343 70846017
Uterine enlargement 16.12 10.36 11 82073 876 70845484
Application site papules 16.06 10.36 5 82079 60 70846300
Depressed level of consciousness 15.93 10.36 163 81921 87268 70759092
Mast cell degranulation present 15.84 10.36 5 82079 63 70846297
Pulse absent 15.80 10.36 34 82050 9296 70837064
Rheumatoid arthritis 15.79 10.36 240 81844 291565 70554795
Drooling 15.79 10.36 25 82059 5411 70840949
Alanine aminotransferase increased 15.69 10.36 103 81981 147377 70698983
Delirium 15.50 10.36 143 81941 74471 70771889
Gastrointestinal disorder 15.48 10.36 66 82018 105361 70740999
Coma scale abnormal 15.41 10.36 31 82053 8085 70838275
Hyperkinesia 15.33 10.36 17 82067 2606 70843754
Respiratory rate decreased 15.30 10.36 23 82061 4759 70841601
Toxic epidermal necrolysis 15.30 10.36 88 81996 39469 70806891
Osteoarthritis 15.29 10.36 40 82044 74107 70772253
Bone density decreased 15.24 10.36 38 82046 11436 70834924
Malaise 15.23 10.36 383 81701 432549 70413811
Renal injury 15.14 10.36 47 82037 16047 70830313
Implant site discharge 15.06 10.36 6 82078 154 70846206
Brain injury 14.99 10.36 36 82048 10581 70835779
Pulmonary renal syndrome 14.95 10.36 9 82075 577 70845783
Blood potassium increased 14.93 10.36 67 82017 27259 70819101
Renal transplant 14.86 10.36 16 82068 2372 70843988
Respiratory moniliasis 14.81 10.36 7 82077 274 70846086
Brief psychotic disorder with marked stressors 14.65 10.36 7 82077 281 70846079
Haematochezia 14.64 10.36 40 82044 73041 70773319
Cardiac hypertrophy 14.60 10.36 13 82071 1529 70844831
Saccadic eye movement 14.60 10.36 6 82078 167 70846193
Asthma 14.48 10.36 208 81876 120585 70725775
COVID-19 14.44 10.36 68 82016 105689 70740671
Melaena 14.42 10.36 27 82057 56328 70790032
Pulmonary oedema 14.33 10.36 152 81932 82126 70764234
Pain in jaw 14.26 10.36 17 82067 42652 70803708
Drug detoxification 14.20 10.36 7 82077 301 70846059
Focal segmental glomerulosclerosis 14.15 10.36 18 82066 3186 70843174
Hyperthyroidism 14.11 10.36 3 82081 20088 70826272
Device computer issue 13.98 10.36 4 82080 35 70846325
Hypoxic-ischaemic encephalopathy 13.98 10.36 28 82056 7280 70839080
End stage renal disease 13.88 10.36 36 82048 11097 70835263
Product quality issue 13.85 10.36 71 82013 30490 70815870
Loss of personal independence in daily activities 13.83 10.36 51 82033 84859 70761501
Renal artery stenosis 13.80 10.36 18 82066 3266 70843094
Rash pruritic 13.75 10.36 33 82051 62958 70783402
Normochromic normocytic anaemia 13.55 10.36 27 82057 6996 70839364
Agranulocytosis 13.53 10.36 16 82068 40282 70806078
General physical health deterioration 13.51 10.36 192 81892 235839 70610521
Multiple sclerosis relapse 13.48 10.36 18 82066 42999 70803361
Hypertrichosis 13.37 10.36 11 82073 1163 70845197
Peripheral swelling 13.34 10.36 193 81891 236370 70609990
Hip arthroplasty 13.25 10.36 8 82076 28032 70818328
Pneumonitis 13.24 10.36 27 82057 54570 70791790
Gamma-glutamyltransferase increased 13.22 10.36 24 82060 50661 70795699
Skin tightness 12.88 10.36 22 82062 5068 70841292
Hypertensive urgency 12.78 10.36 7 82077 375 70845985
Skin disorder 12.71 10.36 69 82015 30288 70816072
Autoimmune enteropathy 12.70 10.36 4 82080 50 70846310
Labelled drug-drug interaction medication error 12.70 10.36 6 82078 24121 70822239
Product tampering 12.69 10.36 6 82078 235 70846125
Chest discomfort 12.66 10.36 88 81996 124293 70722067
Mood swings 12.48 10.36 48 82036 18238 70828122
Educational problem 12.41 10.36 7 82077 397 70845963
Mydriasis 12.36 10.36 44 82040 16109 70830251
Accidental poisoning 12.22 10.36 12 82072 1598 70844762
Pulmonary arterial hypertension 12.19 10.36 12 82072 32843 70813517
Myelodysplastic syndrome 12.10 10.36 10 82074 29775 70816585
Respiratory tract infection 12.05 10.36 19 82065 42379 70803981
Peritoneal dialysis complication 11.92 10.36 14 82070 2282 70844078
Plasma cell myeloma 11.90 10.36 44 82040 73157 70773203
Cytokine release syndrome 11.89 10.36 8 82076 26459 70819901
Blood creatinine increased 11.89 10.36 232 81852 142769 70703591
Nervousness 11.88 10.36 69 82015 31051 70815309
Sinus arrhythmia 11.87 10.36 13 82071 1965 70844395
Blister 11.84 10.36 68 82016 100458 70745902
Product prescribing issue 11.66 10.36 16 82068 3048 70843312
Treatment noncompliance 11.64 10.36 93 81991 46481 70799879
Gun shot wound 11.55 10.36 10 82074 1133 70845227
Mobility decreased 11.43 10.36 71 82013 102928 70743432
Hypersomnia 11.41 10.36 51 82033 20713 70825647
Page kidney 11.41 10.36 4 82080 71 70846289
Renal transplant failure 11.28 10.36 12 82072 1756 70844604
Bladder cancer 11.27 10.36 3 82081 17239 70829121
Skin fibrosis 11.27 10.36 11 82073 1454 70844906
Encephalomalacia 11.23 10.36 10 82074 1176 70845184
Peau d'orange 11.21 10.36 6 82078 307 70846053
Knee arthroplasty 11.11 10.36 14 82070 34287 70812073
Right ventricular failure 11.03 10.36 6 82078 22268 70824092
Left atrial dilatation 11.02 10.36 15 82069 2834 70843526
Joint injury 10.99 10.36 9 82075 26923 70819437
Medical device site erythema 10.97 10.36 4 82080 80 70846280
Retching 10.95 10.36 42 82042 15937 70830423
Gastric hypomotility 10.92 10.36 5 82079 182 70846178
Tendonitis 10.90 10.36 6 82078 22116 70824244
Medical device site swelling 10.87 10.36 4 82080 82 70846278
Coordination abnormal 10.82 10.36 42 82042 16024 70830336
Product preparation issue 10.78 10.36 9 82075 971 70845389
Allergic sinusitis 10.77 10.36 7 82077 514 70845846
Hyporesponsive to stimuli 10.75 10.36 12 82072 1853 70844507
Trichoglossia 10.71 10.36 7 82077 519 70845841
Inadequate analgesia 10.68 10.36 18 82066 4104 70842256
Psychogenic seizure 10.58 10.36 12 82072 1884 70844476
Labile hypertension 10.56 10.36 7 82077 531 70845829
Drug dependence, antepartum 10.51 10.36 3 82081 26 70846334
Femur fracture 10.45 10.36 16 82068 36116 70810244
Cardiopulmonary failure 10.45 10.36 23 82061 6387 70839973
Gastric ileus 10.41 10.36 3 82081 27 70846333
Streptococcal infection 10.38 10.36 26 82058 7845 70838515
SJS-TEN overlap 10.36 10.36 7 82077 548 70845812

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C02AC01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Imidazoline receptor agonists
ATC C02LC01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Imidazoline receptor agonists in combination with diuretics
ATC C02LC51 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Imidazoline receptor agonists in combination with diuretics
ATC N02CX02 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Other antimigraine preparations
ATC S01EA04 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Sympathomimetics in glaucoma therapy
FDA MoA N0000009918 Adrenergic alpha2-Agonists
FDA EPC N0000175554 Central alpha-2 Adrenergic Agonist
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
MeSH PA D000700 Analgesics
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D013565 Sympatholytics
CHEBI has role CHEBI:35569 alpha-adrenergic agonists
CHEBI has role CHEBI:35674 antihypertensive drugs
CHEBI has role CHEBI:66991 sympatholytic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Severe pain indication 76948002
Open-angle glaucoma indication 84494001 DOID:1067
Attention deficit hyperactivity disorder indication 406506008
Increased Intraocular Pressure after Ocular Procedure indication
Ocular hypertension off-label use 4210003 DOID:9282
Gilles de la Tourette's syndrome off-label use 5158005 DOID:11119
Pain off-label use 22253000
Diarrhea off-label use 62315008
Opioid withdrawal off-label use 87132004
Menopausal flushing off-label use 198436008
Smoking cessation assistance off-label use 384742004
Nicotine Withdrawal Symptoms off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Tear film insufficiency contraindication 46152009
End stage renal disease contraindication 46177005 DOID:784
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Bradycardia contraindication 48867003
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Blood coagulation disorder contraindication 64779008 DOID:1247
Hypercalcemia contraindication 66931009 DOID:12678
Hypochloremic alkalosis contraindication 70134007
Decreased respiratory function contraindication 80954004
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Magnetic resonance imaging contraindication 113091000
Perioperative care contraindication 133897009
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Atrioventricular block contraindication 233917008 DOID:0050820
Labor pain contraindication 247412007
Raynaud's phenomenon contraindication 266261006
Syncope contraindication 271594007
Surgical procedure contraindication 387713003
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Myocardial ischemia contraindication 414795007 DOID:3393
Inflammatory dermatosis contraindication 703938007
Vagal Reflex Bradycardia contraindication
Severe Cardiopulmonary Disease contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.5 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2B adrenergic receptor GPCR AGONIST Ki 7.50 CHEMBL CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST EC50 6.70 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST Ki 8.42 CHEMBL CHEMBL
Alpha-1D adrenergic receptor GPCR Ki 6.22 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 6.50 PDSP
Nischarin Membrane receptor Ki 8.05 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.65 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.80 WOMBAT-PK
Multidrug and toxin extrusion protein 1 Transporter IC50 4.48 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.49 CHEMBL
Alpha-1A adrenergic receptor GPCR Ki 6.50 PDSP
Alpha-1B adrenergic receptor GPCR Ki 5.99 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR Kd 6.59 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 8.08 CHEMBL
Alpha-1D adrenergic receptor GPCR AGONIST Ki 6.90 IUPHAR
5-hydroxytryptamine receptor 1A GPCR IC50 5.27 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 9.41 CHEMBL
Alpha-1A adrenergic receptor GPCR EC50 7.05 CHEMBL
Alpha-2A adrenergic receptor GPCR IC50 8.70 CHEMBL
Beta-1 adrenergic receptor GPCR Kd 4.40 CHEMBL
Nischarin Unclassified Ki 6.95 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Ion channel BLOCKER IC50 4.40 IUPHAR
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Ion channel BLOCKER IC50 5.10 IUPHAR
Adrenergic receptor alpha-2 GPCR Ki 8.82 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Ion channel BLOCKER IC50 5 IUPHAR
Alpha-1B adrenergic receptor GPCR EC50 7.08 CHEMBL

External reference:

IDSource
4017850 VUID
N0000146207 NUI
D00281 KEGG_DRUG
4205-91-8 SECONDARY_CAS_RN
142432 RXNORM
4017849 VANDF
4017850 VANDF
C0009014 UMLSCUI
CHEBI:46631 CHEBI
CLU PDB_CHEM_ID
CHEMBL134 ChEMBL_ID
DB00575 DRUGBANK_ID
CHEMBL1705 ChEMBL_ID
D003000 MESH_DESCRIPTOR_UI
2803 PUBCHEM_CID
516 IUPHAR_LIGAND_ID
2624 INN_ID
MN3L5RMN02 UNII
27687 MMSL
381 MMSL
4478 MMSL
4479 MMSL
89106 MMSL
d00044 MMSL
000644 NDDF
004495 NDDF
372805007 SNOMEDCT_US
387121001 SNOMEDCT_US
62782004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9723 INJECTION, SOLUTION 500 ug INTRAVENOUS ANDA 21 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9723 INJECTION, SOLUTION 500 ug INTRAVENOUS ANDA 21 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9724 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 21 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9724 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 21 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2127 TABLET 0.10 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2128 TABLET 0.20 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2129 TABLET 0.30 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-4241 TABLET, EXTENDED RELEASE 0.10 mg ORAL ANDA 19 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-4241 TABLET, EXTENDED RELEASE 0.10 mg ORAL ANDA 19 sections
Clonidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0871 PATCH 0.10 mg TRANSDERMAL ANDA 16 sections
Clonidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0872 PATCH 0.20 mg TRANSDERMAL ANDA 16 sections
Clonidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0873 PATCH 0.30 mg TRANSDERMAL ANDA 16 sections
Clonidine transdermal system HUMAN PRESCRIPTION DRUG LABEL 1 0591-3508 PATCH 0.10 mg TRANSDERMAL ANDA 21 sections
Clonidine transdermal system HUMAN PRESCRIPTION DRUG LABEL 1 0591-3509 PATCH 0.20 mg TRANSDERMAL ANDA 21 sections
Clonidine transdermal system HUMAN PRESCRIPTION DRUG LABEL 1 0591-3510 PATCH 0.30 mg TRANSDERMAL ANDA 21 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0031 PATCH 0.10 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0031 PATCH 0.10 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0032 PATCH 0.20 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0032 PATCH 0.20 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0033 PATCH 0.30 mg TRANSDERMAL NDA 23 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0033 PATCH 0.30 mg TRANSDERMAL NDA 23 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-2572 TABLET 0.10 mg ORAL ANDA 18 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-2574 TABLET 0.30 mg ORAL ANDA 18 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8272 TABLET 0.20 mg ORAL ANDA 12 sections
CLONIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-708 TABLET 0.10 mg ORAL ANDA 20 sections
CLONIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-709 TABLET 0.20 mg ORAL ANDA 20 sections
CLONIDINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10135-710 TABLET 0.30 mg ORAL ANDA 20 sections
Clonidine HydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-257 TABLET, EXTENDED RELEASE 0.10 mg ORAL ANDA 26 sections
Clonidine HydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-257 TABLET, EXTENDED RELEASE 0.10 mg ORAL ANDA 26 sections
Clonidine HydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-302 TABLET, EXTENDED RELEASE 0.20 mg ORAL ANDA 26 sections